Arcus Biosciences [RCUS] vs Praxis Precision [PRAX] Detailed Stock Comparison

Arcus Biosciences Inc.

NYSE
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: Arcus Biosciences Inc. wins in 7 metrics, Praxis Precision Medicines Inc. wins in 7 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Arcus Biosciences Inc. Praxis Precision Medicines Inc. Better
Price-to-Book Ratio 4.99 9.46 Arcus Biosciences Inc.
Debt-to-Equity Ratio 34.71 0.01 Praxis Precision Medicines Inc.
PEG Ratio -7.12 -38.31 Arcus Biosciences Inc.
EV/EBITDA -6.35 -26.32 Arcus Biosciences Inc.
Profit Margin (TTM) -142.92% 0.00% Praxis Precision Medicines Inc.
Operating Margin (TTM) -345.45% 0.00% Praxis Precision Medicines Inc.
Return on Equity -63.26% -45.83% Praxis Precision Medicines Inc.
Return on Assets (TTM) -21.08% -28.69% Arcus Biosciences Inc.
Free Cash Flow (TTM) $-484.00M $-249.12M Praxis Precision Medicines Inc.
1-Year Return 183.76% 807.83% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 12.78 N/A N/A
Enterprise Value $2.39B $8.58B Praxis Precision Medicines Inc.
EV/Revenue Ratio 9.67 N/A N/A
Revenue per Share (TTM) $2 N/A N/A
Earnings per Share (Diluted) $-3.29 $-13.48 Arcus Biosciences Inc.
Beta (Stock Volatility) 0.86 2.97 Arcus Biosciences Inc.
Short % of Float 11.16% 14.21% Arcus Biosciences Inc.

Arcus Biosciences Inc. vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

RCUS
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcus Biosciences Inc.-2.49%-0.46%-8.41%6.38%-6.91%2.45%
Praxis Precision Medicines Inc.8.08%-21.90%-17.38%-12.35%49.84%-2.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcus Biosciences Inc.183.76%20.61%1.16%43.98%43.98%43.98%
Praxis Precision Medicines Inc.807.83%2,210.03%21.08%-16.07%-16.07%-16.07%

Performance & Financial Health Analysis: Arcus Biosciences Inc. vs Praxis Precision Medicines Inc.

MetricRCUSPRAX
Market Information
Market Cap i$3.20B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,560,583391,453
90 Day Avg. Volume i1,285,691416,321
Last Close$23.86$278.93
52 Week Range$7.91 - $28.72$37.19 - $366.52
% from 52W High-16.92%-23.90%
All-Time High$49.10 (Nov 22, 2021)$914.27 (Jan 04, 2021)
% from All-Time High-51.41%-69.49%
Growth Metrics
Quarterly Revenue Growth0.27%N/A
Quarterly Earnings Growth0.27%-1.00%
Financial Health
Profit Margin (TTM) i-1.43%0.00%
Operating Margin (TTM) i-3.45%0.00%
Return on Equity (TTM) i-0.63%-0.46%
Debt to Equity (MRQ) i34.710.01
Cash & Liquidity
Book Value per Share (MRQ)$5.04$34.85
Cash per Share (MRQ)$7.83$21.52
Operating Cash Flow (TTM) i$-482,000,000$-249,068,000
Levered Free Cash Flow (TTM) i$-162,250,000$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Arcus Biosciences Inc. vs Praxis Precision Medicines Inc.

MetricRCUS (Apr 26, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E i-7.12-38.31
PEG Ratio i-7.12-38.31
Price to Sales (TTM) i12.78N/A
Price to Book (MRQ) i4.999.46
Market Capitalization
Market Capitalization i$3.20B$9.60B
Enterprise Value i$2.39B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i9.67N/A
Enterprise to EBITDA i-6.35-26.32
Risk & Other Metrics
Beta i0.862.97
Book Value per Share (MRQ) i$5.04$34.85

Financial Statements Comparison: Arcus Biosciences Inc. vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRCUS (2025)PRAX (2025)
Revenue/Sales i247.00M0
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i523.00M267.12M
Operating Income (EBIT) i-386.00M-326.20M
Operating Margin i-156.3%-
EBITDA i-335.00M-326.06M
EBITDA Margin i-135.6%-
Pre-Tax Income i-353.00M-303.27M
Pre-Tax Income % of Revenue i-142.9%-
Income Tax i0N/A
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-353.00M-303.27M
Profit Margin i-142.9%-

Balance Sheet & Liquidity Metrics

MetricRCUS (2025)PRAX (2025)
Cash & Equivalents i222.00M357.33M
Total Current Assets i1.01B610.91M
Total Current Assets % of Revenue i407.7%-
Total Current Liabilities i231.00M59.77M
Total Current Liabilities % of Revenue i93.5%-
Long-Term Debt i99.00M0
Long-Term Debt % of Revenue i40.1%-
Total Shareholders Equity i631.00M878.14M
Retained Earnings i-1.49B-1.14B
Retained Earnings % of Revenue i-601.2%-
Property, Plant & Equipment i28.00M415,000

Cash Flow Statement Comparison

MetricRCUS (2025)PRAX (2025)
Operating Cash Flow i-469.00M-257.32M
Operating Cash Flow % of Revenue i-189.9%-
Capital Expenditures i-2.00M-56,000
Free Cash Flow i-484.00M-249.12M
FCF Margin i-196.0%-
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricRCUSPRAX
Shares Short i9.88M3.95M
Short Ratio i7.599.07
Short % of Float i11.16%14.21%
Shares Outstanding i125.30M25.20M
Float Shares i88.65M25.78M
% Held by Insiders i29.17%0.40%
% Held by Institutions i74.41%106.12%
% Held by Public i-3.58%-6.52%

Dividend Analysis & Yield Comparison: Arcus Biosciences Inc. vs Praxis Precision Medicines Inc.

MetricRCUSPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A